domingo, 17 de mayo de 2020

Gilead should ditch remdesivir and focus on its simpler ancestor - STAT

Gilead should ditch remdesivir and focus on its simpler ancestor - STAT

First Opinion

Gilead should ditch remdesivir and focus on its simpler and safer ancestor

By VICTORIA C. YAN AND FLORIAN L. MULLER


YICHUAN CAO/SIPA USA VIA AP IMAGES
Gilead Sciences is going all in on its antiviral drug remdesivir. It should also be testing its older drug, GS-441524. It works the same way, only better.

No hay comentarios: